Mereo BioPharma Group (MREO) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
RenovoRx (RNXT) has outperformed Mereo BioPharma Group (MREO) over the past year, gaining 9.9% versus a loss of 81.9%. Over five years, RNXT leads with a -77.8% price change compared with -83.8% for MREO. RenovoRx is the larger company by market cap ($60.0 million vs $59.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MREO | RNXT |
|---|---|---|
| Share price | $0.3752 | $1.33 |
| Market cap | $59.92M | $60.02M |
| 1-day change | +6.35% | -2.92% |
| YTD return | -15.40% | +58.33% |
| 1-year return | -81.91% | +9.92% |
| 5-year return | -83.82% | -77.76% |
| EPS (TTM) | $-0.20 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.37 | $2.59 |
| 52-week low | $0.20 | $0.701 |
| Distance from 52-week high | -84.17% | -48.65% |
| Analyst consensus | none | none |
| Avg. price target upside | +422.39% | +436.09% |
| Average volume | 4.04M | 761.09K |
| Shares outstanding | 159.69M | 45.13M |
| Employees | 39 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed MREO by 91.8 percentage points over the past year.
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Healthcare · Biotechnology · 39 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Healthcare · Biotechnology · 17 employees
MREO vs RNXT FAQ
Which is bigger, Mereo BioPharma Group or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $60.02M compared with $59.92M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, MREO or RNXT?
RNXT returned +9.92% over the past 12 months, compared with -81.91% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Mereo BioPharma Group and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.